TEVA-BICALUTAMIDE
As listed in the register: TEVA-BICALUTAMIDE
50 mg · tablet
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Bicalutamide
- Made by
- Teva Canada Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Bicalutamide). It describes the substance, not this exact product.
Bicalutamide is a non-steroidal androgen receptor inhibitor.
It competitively inhibits the action of androgens by binding to cytosol androgen receptors in the target tissue.
The S (inactive) isomer is metabolized primarily by glucuronidation.
Both the parent and metabolite glucuronides are eliminated in the urine and feces.
Co-administration of bicalutamide with food has no clinically significant effect on rate or extent of absorption.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-04-23
Safety of the active substance
From the US prescribing label for the same active substance (Bicalutamide). It describes the substance, not this exact product.
- Bicalutamide tablets are contraindicated in: Hypersensitivity Bicalutamide tablets are contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet’s components.
- Hypersensitivity reactions including angioneurotic edema and urticaria have been reported.
- Women Bicalutamide tablets have no indication for women, and should not be used in this population.
- Pregnancy Bicalutamide tablets can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ].
The most frequent adverse reaction was hot flashes (53%).
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States10 matching products
Spain24 matching products
- BICALUTAMIDA ACCORD 50 MG · comprimido recubierto con película
- BICALUTAMIDA ALMUS 50 MG · comprimido recubierto con película
- BICALUTAMIDA ARISTO 50 mg bicalutamida · comprimido recubierto con película
- BICALUTAMIDA AUROVITAS 50 mg · comprimido recubierto con película
- BICALUTAMIDA AUROVITAS SPAIN 50 mg bicalutamida · comprimido recubierto con película
- BICALUTAMIDA BLUEFISH 50 MG · comprimido recubierto con película
- BICALUTAMIDA CINFA 50 MG · comprimido recubierto con película
- BICALUTAMIDA COMBIX 50 MG · comprimido recubierto con película
France8 matching products
- BICALUTAMIDE ACCORD 50 mg · comprimé pelliculé
- BICALUTAMIDE ARROW LAB 50 mg · comprimé pelliculé
- BICALUTAMIDE BIOGARAN 50 mg · comprimé pelliculé
- BICALUTAMIDE CRISTERS PHARMA 50 mg · comprimé pelliculé
- BICALUTAMIDE EG 50 mg · comprimé pelliculé
- BICALUTAMIDE EVOLUGEN 50 mg · comprimé pelliculé
- BICALUTAMIDE ZYDUS 50 mg · comprimé pelliculé
- CASODEX 50 mg · comprimé enrobé
Netherlands8 matching products
- Bicalutamide 50 50 mg · filmomhulde tablet
- Bicalutamide 50 PCH 50 mg · filmomhulde tablet
- Bicalutamide Accord 50mg filmomhulde tabletten 50mg · filmomhulde tablet
- Bicalutamide Aurobindo 50 mg 50 mg · filmomhulde tablet
- Bicalutamide Eugia 50 mg 50 mg · filmomhulde tablet
- Bilumide 50 mg 50 mg · filmomhulde tablet
- Biluron 50 mg 50 mg · filmomhulde tablet
- Casodex-50 50 mg · filmomhulde tablet
SwitzerlandNo exact match for this strength and form
Details
| Made by | Teva Canada Limited |
|---|---|
| Active substance | Bicalutamide |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 50 mg |
| Form | tablet |
| Classification | L02BB03 · Cancer treatments and immune-system medicines |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02270226 |
| DPD drug code | 75561 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.